Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › AMLX

Amylyx Pharmaceuticals

AMLX Rare disease Lead: Phase 3 7 Biotech Distilled articles ↓ 35 filings & releases ↓ Cash $240M (Sep 30, 2026) ↓ 7 verdicts ↓ 1 timing quote ↓
MetabolicNeurology Nucleic AcidPeptideSmall Molecule

Market cap $3.79B 128.6M shares (10-Q, Oct 26, 2026) × $29.50 close Nov 6, 2026

Most recent annual filing: 2026-03-03

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. avexitide PBH NDA filingby end of 2026avexitide PBH NDA filing, by end of 2026, material
  2. avexitide LUCIDITY Ph3 readoutNov 15, 2026avexitide LUCIDITY Ph3 readout, Nov 15, 2026, material
  3. Derivative litigation rulingNov 16, 2026Derivative litigation ruling, Nov 16, 2026, routine
  4. AMX0318 IND filing2027AMX0318 IND filing, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

Second Gubra Collaboration · Gubra

Research collaboration with Gubra A/S to identify potential development candidates for a rare endocrine disease of high unmet need; no specific candidate code disclosed.

Discontinued (1)

Capital (as filed)

Cash
$240M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$528M Sep 30, 2026
Operating cash flow
−$33.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$768M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Amylyx Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-11 Watch Amylyx Pharmacueticals (AMLX) - Scientific Deep Dive for Avexitide and Pipeline Products Avexitide's mechanistically sound GLP-1 antagonism in PBH is compelling, but small Phase 2 sample sizes and legal overhang warrant watching rather than buying ahead of the Q3 2026 Phase 3 readout.
  2. 2026-03-28 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Clock Starts Now LUCIDITY enrollment completion locks in the Q3 2026 timeline and removes execution risk, but the watch-list stance is maintained as the binary event still dominates.
  3. 2026-05-08 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) — The Quiet Tells Before the Binary De-risking signals (EAP launch, Shih settlement, clean balance sheet) are building but the binary still dominates and the watch-list stance is unchanged.
  4. 2026-08-07 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Binary Has a Date Topline data is now dated for late August/early September, but the +59% run has pulled forward much of the upside and the watch-list stance is maintained with sizing reflecting a near-term binary.
  5. 2026-08-17 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Alarm Goes Off Tomorrow LUCIDITY topline drops tomorrow morning; the -11.4% pre-event drawdown modestly improves entry math but the distribution is unchanged and the watch-list stance is maintained through the print.
  6. 2026-08-19 Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The Coin Landed Heads LUCIDITY hit its primary endpoint with a 55% placebo-adjusted reduction (p=0.000003) and all secondaries cleared, retiring clinical risk; the remaining risk is commercial and manufacturing, warranting a speculative buy.
  7. 2026-08-20 Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The $500 Million Vote of Confidence The upsized $500M offering priced above the prior close signals strong institutional demand; speculative buy maintained as the story transitions from a data binary to a launch execution question.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (35)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 15, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)